Take a look at the 2023 agenda to find out what CPI, Orchard Therapeutics, ViGeneron, and others will shared with attendees last summer in Amsterdam:

  • Enhancing stability and evaluating CQAs of your viral vectors
  • Process intensification to increase yield and reduce COGS of your viral vector based therapies – whether you are working in cell, gene or viral vector based drugs
  • Scale-up, scale-out or scale down? Defining the right parameters to support rapid commercialisation of your viral vector production while adhering to cGMP compliance
Viral Vector Formulation & Process Dev Europe

Once you have filled out the form, click the 'download' icon on the top right corner of the file to download it.

Having trouble downloading the brochure? Let us know and we’ll email it to you instead.